The estimated Net Worth of Realty Trust Inc Bio Med Re... is at least 305 千$ dollars as of 30 January 2015. Realty Re owns over 26,543 units of Zosano Pharma Corp stock worth over 305,450$ and over the last 10 years Realty sold ZSAN stock worth over 0$.
Realty has made over 1 trades of the Zosano Pharma Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently Realty bought 26,543 units of ZSAN stock worth 291,973$ on 30 January 2015.
The largest trade Realty's ever made was buying 26,543 units of Zosano Pharma Corp stock on 30 January 2015 worth over 291,973$. On average, Realty trades about 26,543 units every 0 days since 2015. As of 30 January 2015 Realty still owns at least 545,447 units of Zosano Pharma Corp stock.
You can see the complete history of Realty Re stock trades at the bottom of the page.
Realty's mailing address filed with the SEC is 17190 BERNARDO CENTER DRIVE17190 BERNARDO CENTER DRIVE, , SAN DIEGOSAN DIEGO, CACA, 9212892128.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over 5,506,679$ worth of Zosano Pharma Corp stock and bought 790,627 units worth 1,835,090$ . The most active insiders traders include M James Barrett、Enterprise Associates 12, L...、Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of 44,258$. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth 58$.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: